Logistic model of likelihood of having a high CD4 count or IgA level greater than the cutoff point for adult patients older than 20 years
| . | Variable . | Category . | n . | OR . | 99% CI . | P value . |
|---|---|---|---|---|---|---|
| Landmark model predicted by CD4 and IgA | ||||||
| Likelihood of having high day-100 CD4 count (>104 × 106/L) | ||||||
| Graft source | BM | 205 | 1.000 | — | .002 (2 df) | |
| PB | 1145 | 1.661 | 1.068-2.583 | .003 | ||
| CB | 280 | 0.749 | 0.433-1.296 | .174 | ||
| GVHD prophylaxis | CNI | 896 | 1.000 | — | <.001 (3 df) | |
| CNI+ATG | 289 | 0.189 | 0.127-0.281 | <.001 | ||
| TCD | 164 | 0.159 | 0.098-0.258 | <.001 | ||
| PTCy | 281 | 0.327 | 0.216-0.496 | <.001 | ||
| Steroid use | No | 943 | 1.000 | — | ||
| Yes | 687 | 0.615 | 0.455-0.829 | <.001 | ||
| Likelihood of having high day-180 CD4 count (>115 × 106/L) | ||||||
| GVHD prophylaxis | CNI | 469 | 1.000 | — | <.001 (3 df) | |
| CNI+ATG | 94 | 0.170 | 0.089-0.324 | <.001 | ||
| TCD | 91 | 0.155 | 0.080-0.300 | <.001 | ||
| PTCy | 130 | 0.460 | 0.246-0.858 | .001 | ||
| Steroid use | No | 436 | 1.000 | — | ||
| Yes | 348 | 0.440 | 0.274-0.706 | <.001 | ||
| Likelihood of having high day-180 IgA (>114 mg/dL) | ||||||
| Steroid use | No | 436 | 1.000 | — | ||
| Yes | 348 | 0.489 | 0.318-0.751 | <.001 | ||
| Landmark model predicted by CD4 only | ||||||
| Likelihood of having high day-180 CD4 count (>115 × 106/L) | ||||||
| Graft source | BM | 200 | 1.000 | — | .001 (2 df) | |
| PB | 1119 | 1.724 | 1.080-2.752 | .003 | ||
| CB | 276 | 1.068 | 0.598-1.906 | .770 | ||
| GVHD prophylaxis | CNI | 885 | 1.000 | — | <.001 (3 df) | |
| CNI+ATG | 284 | 0.239 | 0.159-0.360 | <.001 | ||
| TCD | 157 | 0.186 | 0.114-0.306 | <.001 | ||
| PTCy | 269 | 0.582 | 0.365-0.927 | .003 | ||
| Steroid use | No | 925 | 1.000 | — | ||
| Yes | 670 | 0.549 | 0.399-0.756 | <.001 |
| . | Variable . | Category . | n . | OR . | 99% CI . | P value . |
|---|---|---|---|---|---|---|
| Landmark model predicted by CD4 and IgA | ||||||
| Likelihood of having high day-100 CD4 count (>104 × 106/L) | ||||||
| Graft source | BM | 205 | 1.000 | — | .002 (2 df) | |
| PB | 1145 | 1.661 | 1.068-2.583 | .003 | ||
| CB | 280 | 0.749 | 0.433-1.296 | .174 | ||
| GVHD prophylaxis | CNI | 896 | 1.000 | — | <.001 (3 df) | |
| CNI+ATG | 289 | 0.189 | 0.127-0.281 | <.001 | ||
| TCD | 164 | 0.159 | 0.098-0.258 | <.001 | ||
| PTCy | 281 | 0.327 | 0.216-0.496 | <.001 | ||
| Steroid use | No | 943 | 1.000 | — | ||
| Yes | 687 | 0.615 | 0.455-0.829 | <.001 | ||
| Likelihood of having high day-180 CD4 count (>115 × 106/L) | ||||||
| GVHD prophylaxis | CNI | 469 | 1.000 | — | <.001 (3 df) | |
| CNI+ATG | 94 | 0.170 | 0.089-0.324 | <.001 | ||
| TCD | 91 | 0.155 | 0.080-0.300 | <.001 | ||
| PTCy | 130 | 0.460 | 0.246-0.858 | .001 | ||
| Steroid use | No | 436 | 1.000 | — | ||
| Yes | 348 | 0.440 | 0.274-0.706 | <.001 | ||
| Likelihood of having high day-180 IgA (>114 mg/dL) | ||||||
| Steroid use | No | 436 | 1.000 | — | ||
| Yes | 348 | 0.489 | 0.318-0.751 | <.001 | ||
| Landmark model predicted by CD4 only | ||||||
| Likelihood of having high day-180 CD4 count (>115 × 106/L) | ||||||
| Graft source | BM | 200 | 1.000 | — | .001 (2 df) | |
| PB | 1119 | 1.724 | 1.080-2.752 | .003 | ||
| CB | 276 | 1.068 | 0.598-1.906 | .770 | ||
| GVHD prophylaxis | CNI | 885 | 1.000 | — | <.001 (3 df) | |
| CNI+ATG | 284 | 0.239 | 0.159-0.360 | <.001 | ||
| TCD | 157 | 0.186 | 0.114-0.306 | <.001 | ||
| PTCy | 269 | 0.582 | 0.365-0.927 | .003 | ||
| Steroid use | No | 925 | 1.000 | — | ||
| Yes | 670 | 0.549 | 0.399-0.756 | <.001 |
df, degrees of freedom.